Experimental and validation of significance and accuracy of oxidized low-density lipoproteins and myeloperoxidase in the screening of cardio-vascular disease





cardiovascular disease, myeloperoxidase, oxidized low density lipoprotein, oxidative stress marker


The aim. To access the superiority of myeloperoxidase & oxidized low-density lipoproteins over each other acts as a better predictive marker gaining information regarding the severity of cardiovascular disease.

Materials and methods. 215 subjects are taken into consideration of which 54 are healthy controls, 52 are from stable angina pectoris, 53 are taken from unstable angina pectoris and 56 subjects are from acute myocardial infarction. Lipid profile parameters, oxidative stress markers, plasma myeloperoxidase and plasma oxidized low density lipoproteins were estimated by kit methods, thiobarbituric acid reactive substances method, and colorimetric assay, sandwich and competitive enzyme linked immunosorbent assay techniques, respectively. Results were present as mean ± SD, p-values <0.05 as significant, and Student’s unpaired “t” test. Comparative analysis by box and whiskers plot to check skewness and deviations within the values. Data analysis was performed by software package SPSS version 17.0.

Results. The oxidized low density lipoproteins levels found significantly elevated in all three cases subgroup contrary to insignificant levels of myeloperoxidase in stable angina pectoris compared to control. Box and whisker plot of myeloperoxidase levels showed no skewness in stable angina pectoris (non-significant), whereas unstable angina pectoris and acute myocardial infarction showed right skewness (highly significant), whereas plots of oxidized low-density lipoproteins show extensive interquartile range in the stable angina pectoris subgroup, suggesting scattered deviation in the mean values compared to unstable angina pectoris and acute myocardial infarction subgroup.

Conclusions. The study concluded that significantly elevated level of oxidized low-density lipoproteins in stable angina pectoris, unstable angina pectoris, and acute myocardial infarction subgroups with a scattered deviation of oxidized low density lipoproteins levels in the stable angina pectoris subgroup reflects its low prognostic reliability compared to plasma myeloperoxidase with marginal deviation and in insignificant elevation in stable angina pectoris. Thus, plasma myeloperoxidase and oxidized low density lipoproteins levels serve as independent predictors of cardiovascular disease, but plasma myeloperoxidase levels predict an increased risk over oxidized low density lipoproteins for subsequent cardiovascular events in stable and unstable angina and extend the prognostic information gained from traditional biochemical markers

Author Biographies

Deepti Mandsorwale, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College

PhD, Assistant Professor

Department of Biochemistry

Bindu Sharma, Varun Arjun Medial College & Rohilkhand Hospital

PhD, Associate Professor

Department of Biochemistry


  1. Prabhakaran, D., Jeemon, P., Sharma, M., Roth, G. A., Johnson, C., Harikrishnan, S. et. al. (2018). The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990–2016. The Lancet Global Health, 6 (12), e1339–e1351. doi: http://doi.org/10.1016/s2214-109x(18)30407-8
  2. Herrington, W., Lacey, B., Sherliker, P., Armitage, J., Lewington, S. (2016). Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circulation Research, 118 (4), 535–546. doi: http://doi.org/10.1161/circresaha.115.307611
  3. Abdo, A. I., Rayner, B. S., van Reyk, D. M., Hawkins, C. L. (2017). Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction. Redox Biology, 13, 623–632. doi: http://doi.org/10.1016/j.redox.2017.08.004
  4. Aratani, Y. (2018). Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Archives of Biochemistry and Biophysics, 640, 47–52. doi: http://doi.org/10.1016/j.abb.2018.01.004
  5. Oyenuga, A. O., Couper, D., Matsushita, K., Boerwinkle, E., Folsom, A. R. (2018). Association of monocyte myeloperoxidase with incident cardiovascular disease: The Atherosclerosis Risk in Communities Study. PLOS ONE, 13 (10), e0205310. doi: http://doi.org/10.1371/journal.pone.0205310
  6. Rashid, I., Maghzal, G. J., Chen, Y.-C., Cheng, D., Talib, J., Newington, D. et. al. (2018). Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. European Heart Journal, 39 (35), 3301–3310. doi: http://doi.org/10.1093/eurheartj/ehy419
  7. Ndrepepa, G. (2019). Myeloperoxidase – A bridge linking inflammation and oxidative stress with cardiovascular disease. Clinica Chimica Acta, 493, 36–51. doi: http://doi.org/10.1016/j.cca.2019.02.022
  8. Stewart, J., Manmathan, G., Wilkinson, P. (2017). Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovascular Disease, 6. doi: http://doi.org/10.1177/2048004016687211
  9. Linton, M. R. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W. L., et al.; Feingold, K. R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W. W., Dungan, K. et. al. (Eds.) (2019). The role of lipids and lipoproteins in atherosclerosis. Endotext. South Dartmouth: MDText.com, Inc. Available at: https://www.ncbi.nlm.nih.gov/books/NBK343489/
  10. Orekhov, A. N. (2018). LDL and foam cell formation as the basis of atherogenesis. Current Opinion in Lipidology, 29 (4), 279–284. doi: http://doi.org/10.1097/mol.0000000000000525
  11. Kargin, R., Emiroglu, M. Y., Evlice, M., Celik, M., Toprak, A. E., Avci, A. et. al. (2018). Role of the oxidative stress index, myeloperoxidase, catalase activity for cardiac allograft vasculopathy in heart transplant recipients. Clinical Transplantation, 32 (7), e13273. doi: http://doi.org/10.1111/ctr.13273
  12. Liu, Q., Liu, Y., Shi, J., Gao, M., Liu, Y., Cong, Y. et. al. (2018). Entire Peroxidation Reaction System of Myeloperoxidase Correlates with Progressive Low-Density Lipoprotein Modifications via Reactive Aldehydes in Atherosclerotic Patients with Hypertension. Cellular Physiology and Biochemistry, 50 (4), 1245–1254. doi: http://doi.org/10.1159/000494579
  13. Calmarza, P., Lapresta, C., Martínez, M., Lahoz, R., Povar, J. (2018). Utility of myeloperoxidase in the differential diagnosis of acute coronary syndrome. Archivos de Cardiología de México, 88 (5), 391–396. doi: http://doi.org/10.1016/j.acmx.2017.11.003
  14. Govindarajan, S., Raghavan, V. M., Rao, A. C. (2016). Plasma myeloperoxidase and total sialic acid as prognostic indi- cators in acute coronary syndrome. Journal of Clinical and Diagnostic Research, 10, BC09–BC13. doi: http://doi.org/10.7860/jcdr/2016/20715.8347
  15. Aihua, L., Juan, C., Xiaochen, Y., Zhengang, Z., Yulong, L. (2010). Correlation between the myeloperoxidase genetic polymorphism and coronary artery disease. Journal of clinical cardiology, 26, 25–29.
  16. Kubala, L., Lu, G., Baldus, S., Berglund, L., Eiserich, J. P. (2008). Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clinica Chimica Acta, 394 (1-2), 59–62. doi: http://doi.org/10.1016/j.cca.2008.04.001
  17. Tang, W. W., Wu, Y., Nicholls, S. J., Hazen, S. L. (2011). Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. Clinical Chemistry, 57 (1), 33–39. doi: http://doi.org/10.1373/clinchem.2010.152827




How to Cite

Mandsorwale, D., & Sharma, B. (2022). Experimental and validation of significance and accuracy of oxidized low-density lipoproteins and myeloperoxidase in the screening of cardio-vascular disease. ScienceRise: Medical Science, (2(47), 33–38. https://doi.org/10.15587/2519-4798.2022.254042



Medical Science